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NEWS & VIEWS
Can loss-of-function prion-related diseases exist?
Discovery of mutations of the PrnP gene without typical plaque formation and the characteriz-
ation of two prion receptors led us to postulate a new class of prion-related disease: ‘loss
of function’.
Recently we have described a point mutation (N171S)
in the prion protein gene in a family with psychiatric
illness.1 Previously an identical mutation was reported
in a normal control of a study concerning Creutzfeld–
Jakob disease (CJD).2 We have not provided formal
proof of a link between this mutation and the etiology
of the psychiatric diseases displayed by this family. On
the other hand, finding the mutation in five of six affec-
ted and in only one of six normal siblings is suggestive
of at least some involvement of a polymorphism at pos-
ition 171 in an inherited susceptibility to a still
unknown genetic or epigenetic etiological agent. A
similar scenario was depicted for the polymorphism
encountered at position 129 of the PrnP gene, allelic
homozygosity of which predisposes either to
Gerstmann–Straussler Scheinker or to Familial Fatal
Insomnia.3 Other genetic lesions of the PrnP gene have
been reported which lead to initially psychiatric dis-
orders eventually evolving to classical CJD, with a
fatal outcome.4,5
The human related prion diseases (PRD) are brought
about by conformational changes of the normal cellular
sialylated, GPI-anchored prion glycoprotein (PrPc), a
cell surface molecule predominantly expressed in the
hippocampus and the cerebellum. Such confor-
mational changes can be determined by inherited
mutations or by interaction with an already altered
prion molecule (PrPsc) which can be acquired by infec-
tion.6
The conversion from a predominantly alphahelical
to a beta-pleated sheet conformation may lead to aggre-
gation and deposition of the altered molecules as cyto-
plasmic plaques which represent the hallmark of these
diseases insofar as anatomopathological findings are
considered.7 The psychiatric disorders displayed by
the family that we studied are not characterized by
plaque accumulation. However the involvement of the
hippocampus is pointed out in schizophrenia. MRI
studies have indicated that a significant reduction in
size of the temporal lobe, in particular of the hippo-
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campus and the amygdala, may occur.8 Such findings
have been correlated with a decrease in hippocampal
neuron size, in particular from the subiculum, and the
entorrhinal cortex, in post mortem examinations.9
Although the physiological role of the PrP protein still
eludes us, an indication was provided by studies on
hippocampal slices from PrP null mice (in which the
PrP gene has been deleted), which display GABA-a
receptor mediated fast inhibition and impaired long-
term potentiation.10 Another insight has been provided
by the discovery of at least two putative cell surface
receptors for PrP.11,12 It was speculated that the interac-
tion between PrP (itself a cell surface molecule) and
such a receptor might promote cell–cell heterophilic
interactions necessary to establish neuronal net-
working.11 Clearly, mutations in the genes coding for
such receptors might also impair such interactions alt-
ering PrP function. While plaque-forming PRD can be
classified as deposit or storage diseases, a new category
of PRD seems to be emerging, in which PrP or PrP
receptor mutations lead to functional impairment
rather than deposit formation and could therefore be
classified as loss-of-function diseases.
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